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A Case for Caution:
An Evaluation of Calabrese and Baldwin's
Studies of Chemical Hormesis*
Kevin C. Elliott**
Introduction
Properly extrapolating the effects of toxic chemicals from high
doses to low doses is an ongoing, important, and controversial issue
among toxicologists, risk assessors, and managers. Most bioassays of
chemicals involve a preponderance of high doses because the assays are
designed to show statistically significant evidence for the
carcinogenicity of a chemical. 1 When risk assessors and managers set
exposure guidelines for such a chemical, they typically extrapolate its
effects at low doses by making the assumption that its dose-response
curve is linear in the low-dose region.2 Recent research on the
phenomenon of chemical hormesis may challenge this assumption.
3
Hormesis is a positive biological response produced by extremely
low doses of a biological stressor such as a toxic chemical or ionizing
radiation. It is characterized by a U-shaped dose-response curve in
which inhibitory effects are roughly proportional to dose above the no-
observed-adverse-effect-level (NOAEL) but stimulatory effects are
observed below the NOAEL until the dose drops to zero.4 Although
research supporting the generalizability of this phenomenon appears to
contradict the assumption of linear dose-response curves used in current
* I am indebted to Kristin Shrader-Frechette for her instruction and
encouragement. The development of this paper would not have been possible without
her advice. I thank Tom Miller for a helpful discussion.
** Mr. Elliott is a graduate student in the Program in History and Philosophy of
Science at the University of Notre Dame. He received his B.S. (chemistry and
philosophy) from Wheaton College, IL. Email: Elliott.23@nd.edu.
1 See Edward J. Calabrese & Linda A. Baldwin, Chemical Hormesis: Scientific
Foundations, 11.31 (1998).
2 See Edward J. Calabrese & Linda A. Baldwin, Can the Concept of Hormesis
Be Generalized to Carcinogenisis, 28 Regulatory Toxicology and Pharmacology 230,
230 (1998).
3 See Calabrese & Baldwin, supra note 1, at VIII. 1; see also id.
4 See Edward J. Calabrese & Linda A. Baldwin, Hormesis as a Biological
Hypothesis, 106 Envtl. Health Persp. 357 (Supp. 1998).
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risk-assessment practice, the validity and importance of this research is
currently under discussion. 5
Edward Calabrese and Linda Baldwin (hereafter C and B) recently
completed one of the most thorough examinations of the evidence for
chemical hormesis. 6 They carried out an extensive literature search
with a quantitative methodology designed to uncover evidence for
chemical hormesis in previous toxicology studies.7 They concluded
that chemical hormesis is both a widely generalizable phenomenon 8
and that "the concept of hormesis (i.e., low-dose stimulation/high-dose
inhibition) is counter to the cancer risk assessment practices by U.S.
regulatory agencies such as the Environmental Protection Agency
(EPA), Food and Drug Administration (FDA), and Occupational
Safety and Hazard Association (OSHA) which assume that cancer risk
is linear in the low-dose area." 9 These claims are likely to be
particularly influential because Calabrese is a well-known figure in the
study of the toxicological effects of low-level chemical exposures. 1 0
An earlier paper by Calabrese et al. has been widely cited in support of
the existence of chemical hormesis, 11 and his recent work with Linda
5 See e.g., Ortwin Renn, Implications of the Hormesis Hypothesis for Risk
Perception and Communication, 17 Hum. and Exper. Toxicol. 431 (1998).
6 See ARD Stebbing, Hormesis - The Stimulation of Growth by Low Levels of
Inhibitors, 22 Sci. Total Env't 213 (1982); see also J. Michael Davis & David J.
Svendsgaard, U-Shaped Dose-Response Curves: Their Occurrence and Implications
for Risk Assessment, 30 J. of Toxicol. and Env't Health 71 (1990); see also Edward
J. Calabrese et al., The Occurrence of Chemically Induced Hormesis, 52 Health
Physics 531 (1987).
7 See Calabrese & Baldwin, supra note 1, at 11.31; see also Calabrese &
Baldwin, supra note 4; see also Edward J. Calabrese & Linda A. Baldwin, The Dose
Determines the Stimulation (and Poison): Development of a Chemical Hormesis
Database, 16 Int. J. Toxicol. 545 (1997); see also Edward J. Calabrese & Linda A.
Baldwin, A Quantitatively-Based Methodology for the Evaluation of Chemical
Hormesis, 3 Hum. and Ecol. Risk Assessment 545 (1997).
8 See Calabrese & Baldwin, supra note 1, at 4.
9 Id. at VIII-1; see also Calabrese & Baldwin, supra note 2, at 230.
10 Calabrese is the chairman of the Biological Effects of Low Level Exposures
advisory board, a group of scientists organized to develop a better understanding of
biological responses to low doses of chemical and physical agents. He is editor of the
journal Biological Effects of Low Level Exposures, andahe has organized several
conferences related to the hypothesis of hormesis. See e.g., K.A. Skov, Perspectives
on the Adaptive Response from Studies on the Response to Low Radiation Doses (or
to Cisplatin) in Mammalian Cells, 18 Hum. Exp. Toxicol. 450 (1999).
11 See Calabrese et al., supra note 6 (this article has been cited over 40 times);
see e.g., Harold Boxenbaum et al., Hormesis, Gompertz Functions, and Risk
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Baldwin is cited by those who are evaluating the implications of
chemical hormesis for risk assessment and management. 12
Furthermore, a number of recent articles made claims similar to
those of C and B. For example, in a recent paper, Justin Teeguarden et
al. claimed that the attention that chemical hormesis has received in
recent literature "challenges current approaches to carcinogen testing
that are limited in their usefulness by their narrow focus on linear dose
responses and toxic effects. Indications of hormesis in carcinogenesis
further legitimize the notion that current linear low-dose approaches to
risk assessment and human drug safety studies are flawed." 13
In a paper evaluating the implications of chemical hormesis for
quantitative risk assessment, Sielken and Stevenson made a number of
proposals concerning the risk assessment of toxic chemicals. They
proposed that low-dose risk characterization will need to reflect the
likelihood of beneficial effects at a dose and that sufficiendy small dose
levels are not likely to have any adverse effects. 14 Sielken and
Stevenson state that the communication of uncertainty will need to be
expanded to include lower bounds as well as upper bounds "to reflect
not only how harmful a dose might be but also how beneficial some
doses might be." 15 They also suggest that "greater explicit use of
expert judgment and weight-of-evidence based distributional analyses
will be needed to reflect more of the available dose-response
information." 16 The authors agree that these changes are long overdue.
In addition, the abstract of another recent paper by Johnson and
Bruunsgaard reports that the implications of such non-linearity
[hormesis] are such that governmental regulatory activities and other
Assessment, 19 Drug Metabolism Rev. 195 (1988); see also C.T. De Rosa et al.,
Public Health Implications of Environmental Exposures, 106 Env. Health Persp. 369
(Supp. 1998).
12 See e.g., Justin G. Teeguarden et al., Implications of Hormesis on the Bioassay
and Hazard Assessment of Chemical Carcinogens, 17 Hum. Exp. Toxicol. 254
(1998); Jeffery A. Foran, Regulatory Implications of Hormesis, 17 Hum. Exp.
Toxicol. 441 (1998), see also Renn, supra note 5; see also Skov, supra note 10.
13 Teeguarden, supra note 12, at 257.
14 See Robert L. Sielken, Jr. & Donald E. Stevenson, Some Implications for
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areas of public health administration will be affected to a large extent
once hormesis is widely recognized. 17 Thus, the implications with
regard to environmental intervention and subsequent regulatory
decisions will profoundly affect the political process. 18
According to those authors, chemical hormesis has significant
implications for risk assessment and regulation. So far, however,
governmental agencies are slow to accept implications of chemical
hormesis for risk assessment and management. As Renn reports,(regulatory agencies prefer to ignore this phenomenon as not yet proven
or to deem it irrelevant for pursuing their public mandate." 19 Two
EPA scientists recently claimed that "those who wish to advance the
consideration of biological effects of low-level exposures (BELLE) in
public health regulatory contexts bear a certain burden of proof to show
enough evidence to support a conclusion that a benefit actually results
from low-level exposure to an environmental pollutant." 20 Thus, there
are indications that a public policy conflict is developing with regard to
the risk-assessment implications of chemical hormesis. Furthermore, it
might appear that the conflict is characterized by a growing body of
scientific research that stands in opposition to the unwarranted "inertia'
of governmental regulatory agencies and of society at large.
This article sets forth the proposition that the "inertia" of
government agencies and of society may reflect a very reasonable and
cautious perspective toward current research on chemical hormesis. This
perspective is justified by at least two sets of considerations. Foran
points to both social factors (e.g., political commitment to reduce
pollution to levels that are as low as reasonably achievable) and
scientific/technical factors (e.g., the need to quantify hormetic effects)
that contribute to people's cautious reactions to recent research. 2 1
Articles on risk perception and communication further explore some of
the social factors that relate to chemical hormesis, but those articles
17 See Thomas E. Johnson & Helle Bruunsgaard, Implications of Hormesis for
Biomedical Aging Research, 17 Hum. Exp. Toxicol. 263 (1998).
18 See id.
19 Renn, supra note 5, at 431.
20 J. Michael Davis & William H. Farland, Biological Effects of Low-level
Exposures: A Perspective from U.S. EPA Scientists, 106 Env. Health Persp. 380
(1998).
21 See Foran, supra note 12.
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tend to bracket or assume the generalizability of hormesis and its
scientific implications for policy.2 2 Thus, the social factors partially
explain government policy, but they do not fully justify policy
decisions. The justifiability of the positions taken by government
agencies depends a great deal on the evaluation of the second set of
factors mentioned above: scientific and technical considerations.
Surprisingly, the literature includes few evaluations of this sort.23
With these considerations in mind, this article highlights and
clarifies some of the scientific and technical factors that may justify the
cautious perspective of governmental agencies toward the risk-
assessment implications of chemical hormesis. C and B have performed
a very extensive and high profile study that has (to my knowledge) not
yet been evaluated, so I will proceed by examining their recent work as
a case study. Because a number of authors are making claims similar to
C and B, the scientific and technical issues highlighted in this study
should be broadly applicable to current discussions of chemical
hormesis. The case study consists of three parts: (1) an evaluation of C
and B's scientific evidence for the generalizability of chemical hormesis;
(2) an evaluation of C and B's argument that carcinogenesis is a
hormetic endpoint; and (3) an evaluation of C and B's claim that
hormesis runs counter to current governmental risk assessment
practices. I will conclude with some suggestions concerning the ongoing
research that ought to be pursued if chemical hormesis is to be applied
to risk-assessment policy.
Generalizability of Hormesis
C and B present one of their central conclusions in the executive
summary of their report: "In summary, hormesis appears to be highly
generalizable, not only with respect to the descriptive nature of the
dose-response phenomenon, but also with respect to species, chemical,
and biological endpoint." 2 4 That conclusion could be misleading
22 See e.g., Paul Slovic, If Hormesis Exists... : Implications for Risk Perception
and Communication, 17 Hum. Exp. Toxicol. 439 (1998); see also Renn, supra note
5.
23 I am not aware of any critical examinations of C and B's recent research on
hormesis. Davis & Farland, supra note 20 and Foran, supra note 12, are among the
few articles that have considered scientific/technical issues associated with the
application of chemical hormesis to risk assessment.
24 Calabrese & Baldwin, supra note 1, at 4.
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because it confidently affirms that hormesis is generalizable without
noting two important limitations of the study: (a) this was that a
weight-of-evidence study designed to look only for confirming
instances of hormesis; and (b) the implications that C and B reported
for the low-dose extrapolation of dose-response curves were based on an
examination of only a small minority of the articles found in their
literature search (less than 600 out of 8,500).25
Some background information is necessary to understand those
points. C and B's evaluation of the hypothesis of hormesis started with
a series of literature searches using key words related to hormesis. After
eliminating database replications of articles, the researchers were left
with about 8,500 articles. Then, they performed a manual review of
these studies, yielding about 585 that they deemed "potentially
relevant." 2 6 Unfortunately, they do not explain what exactly they
mean by the expression "potentially relevant." 2 7 Contextually, it
appears that they considered "potentially relevant" articles to be those
that might provide evidence of chemical hormesis. After collecting
those articles, they designed, a priori, qualitative evaluation criteria
based on factors such as number of doses, dose range, reproducibility,
and statistical significance to determine the evidence for hormetic
effects in the 585 articles. Based on those criteria,. evidence of hormesis
(ranging from low to high degrees of evidence) was found in about 350
studies. 2 8 Finally, the 350 studies were reevaluated using more
objective, quantitative criteria, and the studies were once again classified
according to degree of evidence for a hormetic dose-response curve. 2 9
As mentioned above, this study design was limited since it was not
designed to systematically examine the effects of toxic chemicals at low
doses, but rather to collect a variety of cases in which chemicals may
have exhibited hormetic effects. Since the researchers structured this
study to look only for positive instances of hormesis, it is uncertain how
many studies exist that provide evidence for linear dose-response curves
25 See id. at II.1.
26 Id. at 11. 1, 11. 10-11.
27 Id.; see also Calabrese & Baldwin, supra note 4.
28 See id. at 11.1.
29 See id. at 111.10-13.
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in the low-dose region. Francis Bacon recorded the dangers of looking
at evidence supporting only one side of a scientific hypothesis, and his
concerns are still instructive today. "The human understanding when it
has once adopted an opinion . . . draws all things else to support and
agree with it. And though there be a greater number and weight of
instances to be found on the other side, yet these it either neglects and
despises, or else by some distinction sets aside and rejects . . . [so that]
the authority of its former conclusions may remain inviolate." 30
C and B supported their claim that hormesis is generalizable by
showing that hormesis occurred in a wide variety of contexts. 3 1 Yet
this finding probably does not mean as much as it might initially
appear. At present, researchers have not yet systematically examined the
mechanisms that produce chemical hormesis. 32 Thus, researchers are
very limited in their ability to explain its appearance or to predict when
it will or will not occur. Despite the fact that hormesis has been
observed in a number of species at a variety of endpoints with many
different chemicals, it could be that these hormetic effects consistently
occur only under certain conditions (e.g., when an organism is in an
optimal state of health and in an optimal environment). Thus, hormesis
may be generalizable in one sense, but the reader of C and B's study
cannot confidently affirm the significance of this generalizability for
extrapolating the low-dose region of dose-response curves.
In a sense, the second limitation of C and B's study is just a specific
example of the first limitation. It is uncertain whether some of the
7,915 studies that turned up in the literature search, and that were
considered "irrelevant" to the hormetic hormesis, might actually serve
as counterexamples to C and B's claim concerning the generalizability
of hormesis. Their manual review was apparently designed to isolate
only articles that supported the hypothesis of hormesis. Thus, it is
possible that some of the roughly 7,900 rejected articles had a
significant number of low doses and doses below the NOAEL and
would have provided evidence for a linear dose-response curve under
the conditions given in the articles. Considering that C and B did not
elaborate on the characteristics of the numerous studies that they
30 Francis Bacon, The New Organon, 50 (1960).
31 See Calabrese & Baldwin, supra note 4, at 359-60.
32 See id. at 360-61.
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rejected, it is uncertain how much significance to place in the roughly
350 studies (less than 5% of the 8,500 studies that contained key words
related to hormesis) that appeared to show some evidence for the
occurrence of hormesis. Once again, we recognize that C and B
provided examples of hormetic dose-response curves, but the
implications of these curves for the extrapolation of dose-response
curves in general is not clear.
Notably, C and B provide an explanation for the general lack of
toxicology studies demonstrating chemical hormesis. They explain that
the studies that would most likely exhibit hormetic effects (i.e., studies
with a number of doses below the NOAEL) are infrequently performed
since risk assessors want to determine the dose-response curves for high
doses of chemicals. C and B estimate that about 500,000 toxicology
studies have been performed in this century, but only about 10,000
contain six or more doses, about 1,000 have three or more doses below
the NOAEL, and about 900 have doses in the range in which hormetic
effects would be expected to occur.33 Despite the limitations in their
claim that chemical hormesis is widely generalizable, they do explain
that the lack of articles that support the hypothesis of hormesis is most
likely due to the lack of appropriate studies that are performed.
The primary difficulty with that defense is that C and B only
provide a possible explanation for the lack of studies that support
hormesis. If there are about 900 articles that could be expected to
display evidence for or against hormesis, their claim would be
supported more convincingly by an examination of those 900 articles,
reporting the number of articles that displayed positive evidence of
hormesis, the number of articles that displayed evidence that hormesis
did not occur, and a report of factors that could be used to explain or
predict the presence or absence of chemical hormesis. As the evidence
now stands, C and B only show that hormesis occurred in a variety of
cases and that the lack of additional studies demonstrating hormesis
may be due to limitations in study design. It is possible that the lack of
studies demonstrating chemical hormesis reflects the presence of
unknown factors that determine whether a chemical displays a hormetic
or linear dose-response curve under varying conditions.
33 Calabrese & Baldwin, supra note 1, at H.31; see also Calabrese & Baldwin,
supra note 4, at 360-61.
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If the limitations mentioned here are legitimate, it is important to
understand their implications. C and B's study had several goals. One
of their goals was to further the respectability of the hypothesis of
chemical hormesis, and the limitations mentioned here do not seriously
detract from that particular goal. Nevertheless, C and B (along with the
other researchers cited in the introduction) also wish to apply the
study's claims about the generalizability of hormesis to risk
assessment. 3 4 This effort could be seriously misleading if the
limitations mentioned here are not taken into account. It would be
unwise to factor the hypothesis of chemical hormesis into risk-
assessment policy without recognizing that C and B's evidence for the
generalizability of chemical hormesis does not provide systematic
information about the conditions under which hormetic dose-response
curves might be expected to occur. At this point, it would be helpful if
a research group performed an analytic research project that would
make and test predictions about the mechanisms, chemicals, and
conditions that are likely to result in hormetic effects.
Carcinogenesis as a Hormetic Endpoint
Thus far, this paper raises concerns regarding the evidence that C
and B's study provides for chemical hormesis. The rest of this paper
focuses more specifically on the risk-assessment implications of their
study. One of their stated goals was to explore the implications of
chemical hormesis for risk-assessment practices. 3 5 In chapter VIII of
their study, they argued two main points: (1) that the process of
carcinogenesis is a hormetic endpoint; and (2) that this implies that
federal policies for risk assessment are inadequate. The following
discussion evaluates their claim that carcinogenesis is a hormetic
endpoint. Then I will evaluate the implications of this claim for risk-
assessment policy.
C and B's claim that "the recognition that hormetic responses are
widely generalizable with respect to chemical class, animal model,
gender and biological endpoint suggests that the process of
carcinogenesis should likewise be an endpoint where hormetic responses
34 See Calabrese & Baldwin, supra note 1.
35 See id.; see also Calabrese & Baldwin, supra note 2.
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could be anticipated." 3 6 Before I further examine that argument, it is
worth considering whether the process of carcinogenesis can be
coherently referred to as an endpoint. In general, biological endpoints
are a phenomena that can be quantitatively measured (e.g., longevity,
growth, or enzyme activity). Processes are interactive developments that
take place over a period of time and are not necessarily conducive to
quantitative measurement. Although there are a number of endpoints
related to some aspect of carcinogenesis to which C and B refer (e.g.,
DNA repair enzyme activity, damage to DNA, and cell division), it is
not clear that the complex process of carcinogenesis as a whole is an
endpoint that can be quantitatively measured. With this in mind, I
suggest that C and B could make their claims about hormetic effects on
the process of carcinogenesis more coherent by referring to hormetic
effects on a quantifiable endpoint that can partially represent or
correlate with the process of carcinogenesis. Two possible endpoints
might be cancer-related deaths or incidences of cancer-related illness.
For example, one may interpret C and B as claiming that high levels of
exposure to carcinogenic chemicals correlate with statistically significant
incidences of cancer-related illness, but extremely low levels of exposure
to these same chemicals may correlate with incidences of cancer-related
illness that lie below the level of controls.
This analysis may seem to be a case of linguistic or philosophical
hair-splitting, but it serves two important purposes. First, it clarifies the
exact positive effects (e.g., reduction in cancer-related illness) that a
hormetic chemical is supposed to produce. Secondly, it minimizes the
potential for sidestepping the issue being discussed. Referring to the
process of carcinogenesis as an endpoint implies that a chemical could
have a single, straightforward effect on this process. In actuality,
carcinogenesis is a complex process that might be affected in a
multiplicity of ways by a single chemical, and C and B are trying to
argue that this multiplicity of effects can "boil down" to one overall
positive effect. By noting that we are looking at endpoints representing
the overall results of a complex process, we can better distinguish these
endpoints from "simpler" endpoints that represent one aspect of
carcinogenesis and that may not be affected by as many factors.
36 Calabrese & Baldwin, supra note 1, at VIII.1; see also Calabrese & Baldwin,
supra note 2, at 230.
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With this in mind, I return to C and B's suggestion that chemicals
could have hormetic effects on the process of carcinogenesis. I am
translating this suggestion into a more coherent claim that certain
chemicals could have a hormetic effect on endpoints such as incidence
of cancer-related illness that are related to the process of carcinogenesis
as a whole. C and B supported that claim by looking at almost 20
studies in which carcinogens had a hormetic effect on individual
endpoints associated with one of three aspects of carcinogenesis:
initiation, promotion, or tumor development. The studies involved the
effects of carcinogens on such phenomena as DNA repair enzyme
activity, damage to DNA, cell division in the stomach and kidney,
hyperplasia of the urinary bladder, and bladder tumor development. 37
Through those studies, they concluded by suggesting that hormetic
responses for "cancer endpoints" in general (apparently including the
process/endpoint of carcinogenesis) are highly generalizable. 3 8
This argument must be examined. C and B looked at endpoints
related to some aspect of carcinogenesis (e.g., damage to DNA) and
argued that some studies show hormetic effects on those endpoints. C
and B are trying to show that endpoints related to the overall process of
carcinogenesis (e.g., incidence of cancer-related illness) are likely to
have hormetic dose-response curves. Thus, this conclusion is based on
the critical assumption that hormetic effects on endpoints associated
with the process of carcinogenesis as a whole can be defended by
pointing to hormetic effects on endpoints associated with some aspect
of carcinogenesis. That assumption initially appears plausible in C and
B's study because they refer to the process of carcinogenesis as an
endpoint, and they do not make careful distinctions between different
sorts of carcinogenic endpoints. As noted above, they claim, "[t]hat
hormetic responses occurred with such a wide range of cancer endpoints
argues that the phenomenon is highly generalizable." 3 9 My previous
analysis has clarified, however, that endpoints related to the process of
carcinogenesis ought to be distinguished from endpoints associated
with some aspect of carcinogenesis. Endpoints associated with the
37 See Calabrese & Baldwin, supra note 1, at VIII-2-19; see also Calabrese &
Baldwin, supra note 2, at 230-36.
38 See Calabrese & Baldwin, supra note 1, at VIII.34.
39 Id. at VIII.34.
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whole process may be effected in many ways by a single chemical,
whereas the same chemical is likely to have a more unitary effect on an
endpoint associated with one aspect of carcinogenesis. It is troubling
that C and B did not argue for the validity of their assumption.
In fact, there are at least two reasons that the assumption (namely,
that the hormetic nature of endpoints related to carcinogenesis as a
whole can be defended by showing hormetic effects endpoints
associated with some aspect of carcinogenesis) is doubtful. First of all,
as a matter of pure logic, this assumption is very similar to the fallacy of
composition. When this fallacy is committed, properties of the parts of
an entity are transferred to the entity as a whole. For example, by
assuming that the entire U.S. government would work efficiently if
every employee of the government worked efficiently. This would be
an invalid inference if there were so few government employees that the
government as a whole could not get work done efficiently even though
each individual employee worked efficiently. Similarly, it is possible
that low doses of a carcinogen beneficially effect one particular
carcinogenic endpoint while damaging other endpoints and
contributing to an overall propensity for cancer-related illness.
Despite the logical problems with C and B's assumption, a priori
possibility exists that the hormetic nature of endpoints related to some
aspect of carcinogenesis might correlate with a hormetic effect on
endpoints associated with carcinogenesis as a whole. Nevertheless, there
are empirical and logical reasons to doubt this assumption. Davis and
Farland note that toxic chemicals may have a variety of effects at any
particular dose level. 40 Thus, some effects may be beneficial at the
same time that others are harmful.4 1 An example of such multiple
effects is found earlier in C and B's paper. C and B found that
"stimulation of detoxifying enzyme levels observed in the larval form of
a species would be evaluated for its hormetic potential even though this
increased metabolic activity, while beneficial in the short-term, may
have a detrimental effect on other endpoints."42
40 See Davis & Farand, supra note 20, at 380.
41 See id.
42 Calabrese & Baldwin, supra note 1, at 11.5.
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Furthermore, the multiple and combined effects of toxic chemicals
are especially noticeable when these effects are considered with respect
to the complex process of carcinogenesis. As Yamasaki reports:
43
Since carcinogenesis is a multistage process, and each stage
is influenced by a variety of endogenous and exogenous
factors [1,2], estimation of the risk presented by a single
chemical compound may not adequately indicate the overall
risk of the entire carcinogenic process . . . the activity of
initiating agents can only be assessed when promoting agents
are applied, and the activity of promoting agents can only be
estimated when initiating agents have been used. Therefore, it
is inevitable that the dose-response of initiating agents is
influenced by tumor-promoting agents, and the dose-response
of tumor-promoting agents is influenced by the presence of
initiating agents.
With these considerations in mind, it appears unwise to expect
hormetic effects on endpoints associated with the complex process of
carcinogenesis until C and B's assumption is explicitly defended.
One could defend C and B by pointing out that they marshaled the
best possible evidence for their claim considering the difficulties of
dealing with extremely low levels of chemicals. It would be nearly
impossible to do an epidemiological study in which individuals were
exposed to sub-inhibitory amounts of carcinogens for the purpose of
observing statistically significant reductions in cancer rates.44 Thus, C
and B have done "the next best thing;" they have looked for hormetic
effects at the endpoints at which particular carcinogens are known to
contribute to the development of cancer. If a chemical has a positive
effect on that particular endpoint, it may be trifling to suggest that the
chemical could have some other effect on the process of carcinogenesis
through more complicated, interactive mechanisms. In other words, I
may be asking the impossible by asking them to provide a detailed
defense of their assumption, but their assumption has a reasonable
likelihood of being true even though it cannot be defended in full.
43 Hiroshi Yamasaki, Multistage Carcinogenesis: Implications for Risk Estimation,
7 Cancer and Metastasis Reviews 5, 11 (1988).
44 See Calabrese & Baldwin, supra note 1, at VIII.33.
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This debate can be clarified by maintaining focus on what has and
what has not been shown in C and B's study. C and B were wise to
introduce their chapter on carcinogenesis by claiming that the presence
of hormetic effects on a variety of endpoints merely suggests that
endpoints associated with the process of carcinogenesis as a whole
should exhibit hormetic effects. 4 5 I think that the observation of
hormetic effects on endpoints associated with aspects of carcinogenesis
suggests the possibility of hormetic effects on endpoints associated with
carcinogenesis as a whole. Yet, this suggestion should spur further
research. Since it is not confirmed that endpoints associated with the
whole carcinogenic process exhibit hormetic dose-response curve, one
must weigh the plausibility of this assumption against the knowledge of
complications. Some chemicals affect one endpoint positively and other
endpoints negatively. Endpoints associated with the whole process of
carcinogenesis are affected by a combination of factors, and a particular
chemical might impact some of these factors positively while impacting
other factors negatively. Finally, endpoints associated with the process
of carcinogenesis reflect long-term developments that may exhibit
different effects from short-term endpoints associated with some aspect
of carcinogenesis. Thus, C and B's research is exciting and suggestive,
but the application of their conclusions about carcinogenesis to risk-
assessment policy appears premature.
Implications for Risk Assessment and Management
Assuming that the process of carcinogenesis proved to be a
generalizable hormetic endpoint, would this imply that federal policies
for risk assessment are inadequate? As mentioned earlier, C and B claim
that "[t]he concept of hormesis is counter to the cancer risk assessment
practices by U.S. regulatory agencies such as the EPA, FDA, and
OSHA which assume that cancer risk is linear in the low dose area." 4 6
This probably should not be taken as a central conclusion of their
report; it is a summary statement that introduces the twenty studies
demonstrating hormetic effects on individual carcinogenic endpoints.
Nonetheless, this statement makes a host of assumptions, and it is
important to recognize these assumed auxiliary claims if one is to gain a
45 See id. at VIII.1.
46 Id. at VIII.1; see also Calabrese & Baldwin, supra note 2, at 230.
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satisfactory understanding of the scientific and technical issues involved
in applying chemical hormesis to risk-assessment policy.
Davis and Farland point out three reasons that the generalizability
of chemical hormesis may not have significant implications for risk-
assessment policy. First, as previously noted, they claim that toxic
chemicals frequently have multiple effects, some of which might be
hormetic at a particular dose and others of which could be harmful.
Secondly, they note that the EPA must consider particularly sensitive
subpopulations when they formulate their guidelines. Thus, both the
average person and the member of a sensitive subpopulation would have
to experience hormetic effects if a change in policy were to be
warranted. 47 It should also be noted that the variation of hormetic
effects among members of a population might be much more dramatic
than the variation of typical toxic effects. Under normal circumstances,
toxins affect those who are young, elderly, or pregnant more severely
than they affect others. Furthermore, hormetic effects might vary even
more sensitively based on an organism's stress, disease-state, genetic
makeup, or exposure to other environmental factors.4 8 Next, Davis
and Farlan identified that hormetic effects in carefully-controlled
laboratory settings may not mean much in the real world if humans are
already exposed to background levels of chemicals that exceed the
NOAEL. 4 9 In sum, the claim that hormesis runs counter to current
risk-assessment practices assumes three auxiliary claims: (1) hormetic
effects of toxic chemicals are the only relevant effect that the chemicals
have; (2) there is a dose range at which both sensitive and non-sensitive
members of the population could experience hormetic effects from
chemicals; and (3) humans are not already exposed to dose levels that
surpass the chemicals' hormetic dose ranges.
Additionally, there are at least two other auxiliary claims that C
and B are forced to assume if they claim that chemical hormesis runs
counter to risk-assessment policy. First, Foran points out that risk
assessors must consider the concurrent effects of toxic chemicals. If
several hormetic chemicals act via the same mechanism, it must be
47 See Davis & Farland, supra note 20, at 380.
48 See Foran, supra note 12, at 442.
49 See Davis & Farland, supra note 20, at 380.
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determined whether the combined hormetic effects are synergistic or
antagonistic. 50 For example, it is possible to imagine a scenario where
several carcinogenic chemicals in the environment affect the endpoint of
DNA mutations. Even if one toxic chemical was present in sufficiently
low doses to stimulate an over-corrective, positive response, the presence
of several of these toxic chemicals might be sufficient to "swamp" the
body's corrective responses and produce a net harmful amount of DNA
mutation. Thus, humans might be exposed to a very carcinogenic
environment even though each of the toxic items in the environment
would not be individually harmful. Besides considering the joint effects
of several hormetic chemicals, risk assessors would also need to consider
the combination of hormetic effects of some chemicals and toxic
effects of other chemicals. 5 1
Finally, another auxiliary claim is that risk assessors must consider
the difference between short-term effects on single endpoints and long-
term effects on whole organisms. It would not be surprising if some
hormetic effects were beneficial in the short term but harmful in the
long term. For example, C and B argue in their paper that hormesis
should be "viewed within the context of a counteractive response to
perturbations in homeostasis." 52 One would expect a priori that even if
counteractive responses to perturbations in homeostasis had positive
short-term effects on an individual endpoint, they might "wear down"
the organism as a whole and result in negative impacts on the organism
as a whole in the long term. In fact, I have already provided a quote
from C and B demonstrating that the stimulation of detoxifying
enzyme levels in larvae can be a short-term hormetic effect that has
negative long-term effects on the whole organism. 53 Thus, C and B
are also relying on the auxiliary claims that the concurrent effects of
hormetic chemicals with other chemicals yield a net hormetic effect
and that short-term, single endpoint hormetic effects can carry over
into long-term hormetic effects on whole organisms.
C and B could defend the claim that they oversimplified the
implications of hormesis for risk-assessment policy by responding that
50 See Foran, supra note 12, at 441.
51 See id. at 442.
52 Calabrese & Baldwin, supra note 1, at 3.
53 See id. at 11-5.
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they were merely making a summary generalization and that the
auxiliary claims necessary to establish the conflict between hormesis and
risk assessment policy are defensible. For example, C and B examined a
study that presented the effects of caffeic acid on cell division during a
rat's entire lifetime which pointed to hormetic effects. 54 That
hormetic effect would presumably satisfy the auxiliary condition that a
hormetic effect on one endpoint ought to carry over to long-term
hormetic effects on the whole organism. Furthermore, Sielken and
Stevenson suggest that the existence of chemical hormesis would imply
that risk uncertainty characterizations should incorporate expert
judgments. Therefore, some might suggest that the uncertainties
involved in these auxiliary claims could be bridged by expert
judgment. 5 5 Thus, researchers such as C and B may be gradually
arriving at sufficient knowledge about chemical hormesis that they and
other experts could develop some informed judgments about
reasonable risk-assessment implications.
The problem with these five auxiliary claims is that, while possibly
defensible in certain cases, they have not been systematically defended
in C and B's study. They did not mention whether most of the studies
in chapter VIII of their report covered the organisms' entire typical
lifespans. 5 6 The studies do not address whether all human
subpopulations would share hormetic effects at certain dose levels or
whether those dose levels are already part of humans' background
exposure. As for the possibility that expert judgments might alleviate
some of these difficulties, Kristin Shrader-Frechette argued that in cases
in which experts are forced to rely on a number of estimates, models,
and heuristic judgmental strategies, the public may be just as qualified
as the experts to determine appropriate policy for ethically-laden
decisions. 5 7 The lack of systematic evidence for these five significant
and largely unexplored auxiliary claims should be taken as an indication
that experts do not have enough solid information to make more
54 See id. atVIII-10.
55 See Sielken & Stevenson, supra note 14, at 262.
56 See Calabrese & Baldwin, supra note 1, at VIII; see also Calabrese &
Baldwin, supra note 2.
57 See Kristin Shrader-Frechette, Evaluating the Expertise of Experts, 6 Risk 118
(1995).
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reasonable conclusions about the implications of chemical hormesis for
risk-assessment policy than the general public.
It is possible to conceive of a somewhat different objection to the
issues to which I have expressed concern. Perhaps I am partially
confusing the risk management of hormetic chemicals with the risk
assessment of hormetic chemicals. Risk assessment is "the
characterization of the potential adverse health effects of human
exposures to environmental hazards." 58 Risk management, on the
other hand, is "the process of evaluating alternative regulatory actions
and selecting among them."5 9 It could be argued that some of the
complicating factors that this paper addresses (especially a chemical's
combined environmental effects with other chemicals) are only relevant
to risk management, so C and B's claims about risk-assessment policy
do not rely on all of these auxiliary claims.
Although I agree that the distinction between risk assessment and
risk management is an important distinction in principle, it is probably
not applicable in this case. If low doses of numerous hormetic chemicals
were accepted in the environment, the risk assessment for a particular
chemical X could not be based on the dose-response curve for exposure
to that chemical alone. Many chemicals are legislated individually, so it
would be unwise to assume that all other chemicals would be regulated
in such a way that their combined effects with X would be satisfactory.
For all practical purposes, if the hypothesis of hormesis were accepted,
the applicable dose-response curve for X would need to be based on the
effects of X at particular doses in conjunction with the small doses of all
the other chemicals that would be present in the environment. Thus, if a
number of chemicals that exhibited hormetic effects could actually
produce negative effects when present together, it would appear that
even acceptance of the claim that hormesis contradicts risk-assessment
practice depends on a defense of the auxiliary claims that I have
mentioned.
58 Committee on the Institutional Means for Assessment of Risks to Public Health,
Risk Assessment in the Federal Government: Managing the Process 18 (1983).
59 Id.
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Conclusions
As I noted at the beginning of this article, the scientific and
technical issues discussed in this case study should be generally
applicable to discussions of chemical hormesis and its implications for
risk assessment. I chose to use C and B's recent studies of chemical
hormesis as a case study because they performed some of the most
comprehensive work to date on this topic and as such, their research is
likely to be particularly influential. My concerns should not be taken as
an indication that C and B have done poor work. Rather, my goal is to
illustrate that the best work in the field still necessitates further
investigations concerning: (1) the generalizability of hormesis; (2) the
hormetic nature of endpoints associated with the total process of
carcinogenesis; and (3) the implications of hormesis for risk assessment.
C and B's literature search legitimized further studies of hormesis by
bringing attention to numerous toxicology studies in which hormetic
effects can now be recognized after-the-fact. However, even as they
noted, a literature search of this sort has strengths and weaknesses. The
benefit of this after-the-fact evaluation is that hormetic effects were less
likely to be produced by researcher bias. The disadvantage is that the
original studies were not optimally designed for the purpose of
studying chemical hormesis. 6 0 As future researchers respond to C and
B's work and pursue studies that are specifically designed to examine
chemical hormesis, hopefully they will address the concerns that are
developed in this paper.
I would suggest that all future research concerning the
generalizability of hormesis should take an analytic approach rather
than a weight-of-evidence approach. C and B's approach was sufficient
for bringing chemical hormesis to people's attention, but an analytic
approach would isolate factors that explain and predict hormetic effects
and provide more systematic information about the low-dose region of
dose-response curves. It is this sort of systematic, explanatory, and
predictive information that can ground risk-assessment policy. It is also
important that further research is developed to prove if and when
endpoints associated with the complex process of carcinogenesis may
display hormetic dose-response curves. This is due to the weaknesses of
epidemiological studies in showing the small positive effects that are
6D See Calabrese & Baldwin, supra note 1, at VIII-32-33.
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characteristic of hormesis.6 1 It may be necessary to develop new and
creative means to show when the hormetic effects of a chemical on an
endpoint, associated with some aspect of carcinogenesis, can be used to
predict a hormetic effect on an endpoint associated with the overall
process of carcinogenesis. It is important that researchers and policy
makers maintain the distinction between these two very different sorts
of "carcinogenic endpoints." Finally, the third section of this paper
provides a compilation of auxiliary claims that ought to be considered
if chemical hormesis is to be applied to current risk-assessment practice.
These five claims suggest that experts may not be qualified to affirm
conflicts between hormesis and risk-assessment policy until further
research is accomplished. Hopefully, the arguments developed in this
article will improve and spur this future research, considering that C
and B's findings "should provide a strong incentive for further
development of this area of inquiry given its potential to enhance
understanding of responses at realistic levels of exposures."
62
61 See Calabrese & Baldwin, supra note 2, at 230.
62 Id. at 240.
